Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation

Clinical Genetics

Volumn 62, Issue 2, 2002, Pages 135-146

  Wehner, Markus ^a   Rueffert, H ^a   Koenig, F ^a   Neuhaus, J ^a   Olthoff, D ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Calcium signaling; Genetics; Human; Malignant hyperthermia

Indexed keywords

CAFFEINE; CALCIUM ION; CHLOROCRESOL; HALOTHANE; INHALATION ANESTHETIC AGENT; METHIONINE; MUSCLE RELAXANT AGENT; RYANODINE RECEPTOR; THREONINE;

ADOLESCENT; ADULT; CALCIUM CELL LEVEL; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE PREDISPOSITION; FEMALE; FLUORESCENCE ANALYSIS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; MYOTUBE; PATHOGENICITY; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; SATELLITE CELL; SENSITIVITY ANALYSIS; WILD TYPE;

AMINO ACID SUBSTITUTION; CAFFEINE; CALCIUM; CRESOLS; FEMALE; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE FIBERS; MUSCLE, SKELETAL; MUTATION; PEDIGREE; POTASSIUM CHLORIDE; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM;

EID: 0036705958     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0004.2002.620206.x     Document Type: Review

References (51)

1. Jurkatt-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve 2000: 23: 4-17.
2. Olthoff D. Fulminant malignant hyperthermia crisis. In: Schulte am Esch, J, Scholz, J, Wappler, F, eds. Malignant Hyperthermia. Lengrich: Pabst Science Publishers, 2000: 32-36.
3. MacLennan DH, Duff C, Zorzato F et al. The ryanodine receptor gene: a candidate gene for preposition to malignant hyperthermia. Nature 1990: 343: 559-561.
4. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutation in malignant hyperthermia and central core disease. Hum Mutat 2000: 15: 410-417.
5. McCarthy TV, Healy JMS, Heffron JJA et al. Localization of malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990: 343: 562-564.
6. Philips M, Fujii J, Khanna VK et al. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics 1996: 34: 24-41.
7. Brown RL, Pollock AN, Couchman KG et al. A novel ryanodine mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 2000: 9: 1515-1524.
8. Rueffert H, Kraus H, Olthoff D, Deutrich C, Froster UG. Identification of a novel mutation in the ryanodine receptor gene (RyR1) in patients with malignant hyperthermia. Hum Mutat 2001: 17: 238.
9. Sambuughin N, Nelson TE, Jankvic J et al. Identification and functional characterization of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord 2001: 11: 530-537.
10. Tilgen N, Zorzato F, Halliger-Keller B et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001: 10: 2879-2887.
11. Manning BM, Quane KA, Ording H et al. Identification of novel mutation in the ryanodine-receptor gene (RyR1) in malignant hyperthermia: genotype-phenotype correlation. Am J Hum Genet 1998: 62: 599-609.
12. Ørding H, for the European Malignant Hyperthermia Group. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. Acta Anaesthesiol Scand 1997: 41: 955-966.
13. MacLennan DH. Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol 1995: 8: 397-401.
14. Fagerlung TH, Ørding H, Bendixen D, Islander G, Ranklev E, Berg K. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation. Clin Genet 1997: 52: 416-421.
15. Isaacs H, Badenhorst M. False-negative results with muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993: 79: 5-9.
16. Brinkmeier H, Krämer J, Krämer R et al. Malignant hyperthermia causing Gly2435Arg mutation of the ryanodine receptor facilitates ryanodine-induced calcium release in myotubes. Br J Anaesth 1999: 83: 855-861.
17. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 1999: 96: 4164-4169.
18. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. Biochemistry 1997: 272: 26332-26339.
19. Censier K, Urwyler A, Zorzato F, Treves S. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. J Clin Invest 1998: 101: 1233-1242.
20. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility Br J Anaesth 1984: 56: 1267-1269.
21. Neville C, Rosenthal N, McGrew M, Bogdanova N, Hauschka S. Skeletal muscle cultures. Methods Cell Biol 1998: 52: 85-116.
22. Ronald EA, Temm-Grove CJ, Shannon MS, Rice G. Skeletal muscle satellite cell cultures. Methods Cell Biol 1998: 52: 155-176.
23. Rosenblatt J, Lunt AI, Parry DJ, Patridge TA. Culturing satellite cells from living single muscle fiber explants. In Vitro Cell Dev Biol Anim 1995: 31: 773-779.
24. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985: 260: 3440-3450.
25. Edom-Vovard E, Mouly V, Barbet JP, Butler-Browne GS. The four populations of myoblasts involved in human limb muscle formation are present from onset of primary myotube formation. J Cell Sci 1999: 112: 191-199.
26. Ven PFM, Schaart G, Jap PHK, Sengers RCA, Stadhouders AM, Ramaekers FCS. Differentiation of human skeletal muscle cells in culture: maturation as indicated by titin and desmin striation. Cell Tissue Res 1992: 270: 189-198.
27. Wehner M, Neuhaus J, König F, Olthoff D. Funktionelle Charakterisierung eines Acetylcholinrezeptors in humanen Myotubes [Functional characterization of an acetylcholine receptor in human myotubes]. Potsdam, Germany: ABBSA Anaesthesia Meeting, March 2001.
28. 2+ release. J Physiol 2000: 526: 507-514.
29. + and caffeine in cultured skeletal muscle cells of embryonic chicken. Pflügers Arch Eur J Physiol 1999: 438: 827-836.
30. Tarroni P, Rossi D, Conti A, Sorrentino V. Expression of the ryanodine receptor type 3 calcium release channel during development and differentiation of mammalian skeletal muscle cells. J Biol Chem 1997: 272: 19808-19813.
31. 2+ release in normal and ryanodine receptor type 3 (RyR3)-deficient mouse myotubes. J Physiol (Lond) 1998: 513: 3-9.
32. Flucher BE, Andrews SB, Fleischer S, Marks AR, Caswell A, Powell JA. Triad formation: organization and function of the sarcoplasmic reticulum calcium release channel and triadin in normal and dysgenic muscle in vitro. J Cell Biol 1993: 123: 1161-1174.
33. 2+ concentrations. Cell Calcium 1991: 12: 29-37.
34. 2+ release channels. J Biol Chem 1999: 274: 693-702.
35. Lopez JR, Alamo L, Caputo C, Wikinski J, Ledezma D. Intracellular ionized calcium concentration in muscles from humans with malignant hyperthermia. Muscle Nerve 1985: 8: 355-358.
36. 2+] measured in vivo in patients susceptible to malignant hyperthermia. Anesthesiology 1992: 76: 711-719.
37. Berridge MJ. Elementary and global aspects of calcium signalling. J Exp Biol 1997: 200: 315-319.
38. 2+ ions from human malignant hyperthermia-susceptible sarcoplasmic reticulum. Biochem Pharmacol 2001: 61: 1479-1485.
39. Gallant EM, Jordan RC. Porcine malignant hyperthermia: genotype and contractile threshold of immature muscles. Muscle Nerve 1996: 19: 68-73.
40. Gallant EM, Lentz LR. Excitation-contraction coupling in pigs heterozygous for malignant hyperthermia. Am J Physiol 1992: 262: C422-C426.
41. Struk A, Lehmann-Horn F, Meltzer W. Voltage-dependent calcium release in human malignant hyperthermia muscle fibers. Biophys J 1998: 75: 2402-2410.
42. Hermann-Frank A, Richter M, Sarközi S, Mohr U, Lehmann-Horn F. 4-chloro-m-cresol, a potent and specific activator of skeletal muscle ryanodine receptor. Biochim Biophys Acta 1996: 1289: 31-40.
43. 2+ release. Mol Pharmacol 1993: 44: 1192-1201.
44. 2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation with malignant hyperthermia. Biochem J 1994: 301: 661-665.
45. Baur CP, Bellon L, Felleiter P et al. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 2000: 90: 200-205.
46. Hermann-Frank A, Richter M, Lehmann-Horn F. 4-chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle. Biochem Pharmacol 1996: 52: 149-155.
47. 2+ channel/ryanodine receptor: modulation by endogenous effectors, drugs and disease states. Pharmacol Rev 1997: 49: 1-51.
48. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989: 69: 511-515.
49. 2+ content in intact amphibian skeletal muscle fibers with 4-chloro-m-cresol. Cell Calcium 1999: 25: 227-235.
50. Urwyler A, Deufel T, McCarthy T, West S, for the European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001: 86: 283-287.
51. Brandt A, Schleithoff L, Jurkatt-Rott K, Klingler W, Baur C, Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Human Mol Genet 1999: 8: 2055-2065.